A major risk of breast cancer screening may have been overestimated for decades
A new analysis of breast cancer screening studies suggests that overdiagnosis from mammograms is much lower than previously believed. Researchers reexamined major trials and found that the rate of overdiagnosis is likely below 5%, not 30% to 50% as some earlier estimates suggested. The findings could change how the risks of screening are understood and communicated to patients.
A reanalysis of breast cancer screening trials found that overdiagnosis rates are much lower than previously thought, with estimates now below 5% instead of 30% to 50%. The study accounted for factors like follow-up time and continued screening after trials ended.
This finding could help clarify the risks and benefits of breast cancer screening, leading to more informed decisions for patients and better public health messaging. It challenges long-held concerns about overdiagnosis and may reduce unnecessary anxiety about screening.
The study provides a clearer, more accurate understanding of a complex medical issue, helping people make informed choices. It highlights the value of reexamining past research to ensure public health recommendations are based on the best available evidence.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.